RheumNow’s expanded coverage of the #EULAR2022 Annual meeting is sponsored in part by Bristol-Myers Squibb. All content is chosen by RheumNow & its Faculty.

#Plenary OP0066. Consider Whipple Dz in pts inflammatory rheum dz Screen with PCR saliva/stool samples, confirm with duodenal bx or PCR on joint fluid. pts on doxycycline and HCQ can lead to rapid remission. @rheumnow https://t.co/VcGp8pr3dT

NORD-STAR substudy looking at anticoagulant effects. Important as RA assoc. ⬆️DVT/PE. DMARDs improve haemostatic imbalance, with bDMARDs stronger effect than csDMARD (may relate to better disease control with this) @RheumNow #EULAR2022 OP0059 https://t.co/TKwAZMOZjY https://t.co/IazrfD7z7k

• EULAR Abstract Archive

#POS0186 #EULAR2022 AURORA2 (Extension of original RCT to 2 years) showed: 💠#lupus nephritis patients on voclosporin maintained meaningful low uPCR and stability of eGFR at 2yrs 💠No unexpected safety signals @RheumNow https://t.co/lnohgW7BsK

Rahman et al. Factors associated with fatigue and its improvement in trials IL23i guselkumab. Disease activity/function (34%), joints (16%), skin (12%) but 38.5% of fatigue variability remains unexplained. @RheumNow #EULAR2022 OP0025 https://t.co/C08R0IWM3S https://t.co/QnCvPwEwKS

• EULAR Abstract Archive

Pedersen et al report 6-fold mortality⬆️over 10 years in RA patients with co-existent depression. Even stronger effect in younger patients (<55) @RheumNow #EULAR2022 OP0067 https://t.co/vYYTmTnstQ https://t.co/xKgMu7zaOA

• EULAR Abstract Archive

NORD-STAR TRIAL drug does better in ttmt naive eRA? 48wks CDAI remission ▶️ w/ ABA and CERTO PEG vs. MTX+ GCs while TCZ not stat ▶️. Is the difference clinically sufficient to recommend these in first intention over MTX ? not convinced 🧐 OP0058 #EULAR22 @rheumnow

#EULAR OP0067 Incident depression is critical RA co-morbidity! 🚨>6x risk of death in 10 year follow-up🚨 Depression defined as 1st filling of anti-depressants ▶️Bias likely contributes, esp including neuropathic medications such as duloxetine, but data is staggering @RheumNow https://t.co/xpQPDLonLj

Screen for depression in RA patients! From the #DANBIO registry of 11,000 pts, they found 6X ⬆️mortality in pts w/#RA and #depression . The mortality curve separates early. #Plenary OP0067 @rheumnow #EULAR2022 https://t.co/qfjyejGVzQ

Damien et al on Whipple's Disease presenting as RMD. 73 cases (wow!) Treat Whipples, 93% remission, 94% off DMARD @RheumNow #EULAR2022 OP0066 https://t.co/XQnQq4RNcq

• EULAR Abstract Archive

#EULAR2022 POS0241 shows JAKi ⬇️ pain catastrophization/central sensitization in RA patient via CSI (Central Sensitization Inventory) and (PCS) Pain Catastrophizing Scale. No decrease of articular inflammation on ultrasound with JAKi shown, but study had just 22 pts @RheumNow

Bimekizumab (dual IL-17F and IL-17A inhibitor) phase 3 study for treatment of active ankylosing spondylitis demonstrated ASAS40 improvement at wk 14 (44% vs. 25%). #EULAR2022 @RheumNow #ABSTOP0019 https://t.co/eohvNFG3GS

Sustained benefits #voclosporin in #LupusNephritis AURORA2 - 2 year study POS0186: 👉no unexpected AEs; rate of AEs⬇️over time 👉COVID19 seen in 12 controls, 7 VCS 👉4 deaths w/control arm vs 0 deaths w/ VCS 👉GFR & sCr & reduction in UPCR remained stable #EULAR2022 @rheumnow

10 year study showed NSAIDs associated with slowing radiographic progression in axSpA patients. mSASSS progression numerically lower in COX2i pts compared to non-selective NSAIDs. @RheumNow #EULAR2022 #ABSTOP0021 https://t.co/dfz3rseikl

#EULAR2022 OP0066 French retrospective obs study 2019-2021 with 73 cases of Whipples disease treated for rheum disease ▶️M/F ratio 3, middle aged ▶️1/2 met RA criteria ▶️Peripheral jts, 1/3 had axial involvement ▶️Rx: HCQ, Doxi - 80% cured, DMARD stopped in >90% cases @RheumNow https://t.co/t7zlDrPfJB